| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/30/2001 | CN1297349A Adhesive preparations |
| 05/29/2001 | US6239256 Isolated muteins of proteins SCP-1, and compositions containing the mutein |
| 05/29/2001 | US6239181 Method for preventing and treating peripheral neurophathy by administering selegiline |
| 05/29/2001 | US6239180 Transdermal therapeutic device and method with capsaicin and capsaicin analogs |
| 05/29/2001 | US6239176 Administering to treat blood disorders like anemia; wound healing, anticarcinogenic and antiproliferative agents; genetic disorders |
| 05/29/2001 | US6239172 Mixture of angiogenic growth factor and l-arginine; brain and cardiovascular disorders |
| 05/29/2001 | US6239170 Applying 5-lipoxygenase inhibitor |
| 05/29/2001 | US6239167 Antitumor compositions containing taxane derivatives |
| 05/29/2001 | US6239164 Immunophilin affinity; nonimmunosuppressant |
| 05/29/2001 | US6239154 Arylacetamides, agonists at kappa opioid receptors. |
| 05/29/2001 | US6239153 Insulin sensitivity enhancer with squaline synthesis inhibitor, which shows a potent depressive effect on diabetic hyperglycemia, |
| 05/29/2001 | US6239125 Antiviral agents against herpes viruses. |
| 05/29/2001 | US6239124 Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin |
| 05/29/2001 | US6239116 Immunostimulatory nucleic acid molecules |
| 05/29/2001 | US6239114 Triterpene derivatives, antitumor |
| 05/29/2001 | US6239113 Topical treatment or prevention of ocular infections |
| 05/29/2001 | US6238900 Nucleotide sequence coding enzymatic polypeptide; for the prevention of bacterial infections; bactericides |
| 05/29/2001 | US6238887 Ribosome recycling factor (FRR) of Staphylococcus aureus |
| 05/29/2001 | US6238883 Neurotransmitter transporter SC6 |
| 05/29/2001 | US6238882 Nucleotide sequence from streptococcus; diagnosis; drug screening for new bactericides; primers; probes; antibodies; vaccines |
| 05/29/2001 | US6238881 Nucleotide sequence which codes for p115 rho-guanine exchange factor involved in cell signalling; therapeutics; diagnostics; recombinant culture production; antibodies; probes |
| 05/29/2001 | US6238878 FVlla/TF activity inhibiting compounds |
| 05/29/2001 | US6238702 High load formulations and methods for providing prolonged local anesthesia |
| 05/29/2001 | US6238673 Drying grape extract |
| 05/29/2001 | US6238666 Polypeptide |
| 05/29/2001 | US6238659 Administering a compound influencing the cellular redox state which is a pyrrolidine dithiocarbamate or a derivative and a cytokine |
| 05/29/2001 | US6238650 Said sunscreen active ingredient is in the form of sol-gel microcapsules containing at least one sunscreen compound. |
| 05/29/2001 | US6238647 Anticholinergic medicament which is selected from the group consisting of ipratropium, atropine, oxitropium and salts thereof |
| 05/29/2001 | CA2064915C Tumour necrosis factor binding ligands |
| 05/29/2001 | CA2019273C Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
| 05/25/2001 | WO2001036979A2 Placental human neurokinin b precursor |
| 05/25/2001 | WO2001036977A2 Identification of disease markers involving mass-based-separation |
| 05/25/2001 | WO2001036686A2 Genomic polymorphism for predicting therapeutic response |
| 05/25/2001 | WO2001036684A2 Mammalian toxicological response markers |
| 05/25/2001 | WO2001036641A2 DOUBLE-STRANDED RNA RECEPTOR (dsRNA-R) AND METHODS RELATING THERETO |
| 05/25/2001 | WO2001036629A1 Transfer compounds, the production and the use thereof |
| 05/25/2001 | WO2001036628A1 Methods of reversing drug resistance in cancer cells |
| 05/25/2001 | WO2001036610A1 Human enzymes of the metalloprotease family |
| 05/25/2001 | WO2001036605A2 2786, a human aminopeptidase |
| 05/25/2001 | WO2001036604A2 Nucleic acids encoding endotheliases, endotheliases and uses thereof |
| 05/25/2001 | WO2001036487A2 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| 05/25/2001 | WO2001036486A2 Scfv antibodies against disease associated molecules |
| 05/25/2001 | WO2001036479A1 G-protein coupled receptor |
| 05/25/2001 | WO2001036472A2 Compositions and methods for regulating tumor-associated antigen expression |
| 05/25/2001 | WO2001036470A2 Methods and compositions for detection and treatment of breast cancer, based on breast cancer-associated polypeptides |
| 05/25/2001 | WO2001036467A2 Mammalian receptor proteins; related reagents and methods |
| 05/25/2001 | WO2001036462A2 Protein c derivatives |
| 05/25/2001 | WO2001036461A2 Compositions and methods for regulating tumor-associated antigen expression |
| 05/25/2001 | WO2001036416A1 Novel thiazolidinedione derivatives as antidiabetic agents |
| 05/25/2001 | WO2001036388A1 Aza compounds having neuronal activity |
| 05/25/2001 | WO2001036007A2 Compositions of a combination of radioactive therapy and cell-cycle inhibitors |
| 05/25/2001 | WO2001035995A2 Tr3-specific binding agents and methods for their use |
| 05/25/2001 | WO2001035988A1 Use of glp-1 agonists for the inhibition of beta cell degeneration |
| 05/25/2001 | WO2001035979A2 Combined pde3 and pde4 inhibitor therapy for the treatment of obesity |
| 05/25/2001 | WO2001035975A2 Treatment of subnormal bone mineral density |
| 05/25/2001 | WO2001035974A2 Aplidine treatment of cancers |
| 05/25/2001 | WO2001035970A1 Viruses for the treatment of cellular proliferative disorders |
| 05/25/2001 | WO2001035963A1 Use of h1 antagonist and a safe steroid to treat eye conditions |
| 05/25/2001 | WO2001035961A1 Methods of treating vascular diseases characterized by nitric oxide insufficiency |
| 05/25/2001 | WO2001035959A1 Use of thiazole derivatives for treatment/prevention of p38 kinase mediated disorders |
| 05/25/2001 | WO2001035956A1 USE OF NSAIDs FOR THE TREATMENT OF PANCREATIC CANCER |
| 05/25/2001 | WO2001035949A2 Treatment or systemic lupus erythematosus (sle) with dehydroepiandrosterone |
| 05/25/2001 | WO2001035948A2 Neurophilin ligands for treating ocular conditions |
| 05/25/2001 | WO2001035943A2 Dextrose and insulin fluid formulation for intravenous infusion |
| 05/25/2001 | WO2001035942A2 Analgesic compositions containing buprenorphine |
| 05/25/2001 | WO2001035937A2 Lipid complex of alkycyclines |
| 05/25/2001 | WO2001035935A2 Inhibitors of endo-exonuclease activity such as pentamidine for the treatment of cancer |
| 05/25/2001 | WO2001035929A2 Biodegradable polymer composition |
| 05/25/2001 | WO2001035905A2 Personal care articles comprising cationic polymer coacervate compositions |
| 05/25/2001 | WO2001035903A2 Compositions and methods for regulating tumor-associated antigen expression |
| 05/25/2001 | WO2001035899A2 Inhibitors of helicobacter pylori induced gastrointestinal diseases |
| 05/25/2001 | WO2001035883A1 Transdermal delivery system for alkaloids of aconitum species |
| 05/25/2001 | WO2001035739A1 Use of polysiloxanes containing quaternary amino groups as formulation auxiliary agents, and agents containing the same |
| 05/25/2001 | WO2001013909A3 Compositions and methods for treating opiate intolerance |
| 05/25/2001 | WO2001013905A3 Methods for the treatment of mental and vascular disorders |
| 05/25/2001 | WO2001010446A3 Formulations for parenteral use of estramustine phosphate and albumin |
| 05/25/2001 | WO2001008693A3 Combination therapy using pentafluorobenzenesulfonamide and platin compound |
| 05/25/2001 | WO2001006005A3 Diagnostic method comprising wt1 sequences |
| 05/25/2001 | WO2001005362A3 Emulsifier-free finely dispersed water-in-oil-type systems |
| 05/25/2001 | WO2001004349A3 Method for the diagnosis or the prognosis of alzheimer disease therapeutical composition for preventing or treating alzheimer disease |
| 05/25/2001 | WO2001000223A3 Multiple agent diabetes therapy |
| 05/25/2001 | WO2000078330A3 Adenosine diphosphatase and activators thereof and their medical uses |
| 05/25/2001 | WO2000078320A8 Cartilage enhancing food supplements and methods of preparing the same |
| 05/25/2001 | WO2000067793A8 Death domain containing receptor 4 |
| 05/25/2001 | WO2000064469A3 Use of glucose-6-phospate isomerase and antibodies thereto for the diagnosis and therapy of arthritis, and test of anti-arthritic compounds |
| 05/25/2001 | WO2000059489A3 Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites |
| 05/25/2001 | WO2000021558A9 Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway |
| 05/25/2001 | WO2000010588A3 Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs |
| 05/25/2001 | WO2000010582A8 Probiotic, lactic acid-producing bacteria and uses thereof |
| 05/25/2001 | WO1999063087A8 G-protein coupled receptor, named 2871 receptor |
| 05/25/2001 | CA2732120A1 Endogenous and non-endogenous versions of human g protein-coupled receptors |
| 05/25/2001 | CA2720361A1 Viruses for the treatment of cellular proliferative disorders |
| 05/25/2001 | CA2396428A1 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
| 05/25/2001 | CA2392109A1 Mammalian receptor proteins; related reagents and methods |
| 05/25/2001 | CA2392093A1 Use of nsaids for the treatment of pancreatic cancer |
| 05/25/2001 | CA2392090A1 G-protein coupled receptor |
| 05/25/2001 | CA2392076A1 Human enzymes of the metalloprotease family |
| 05/25/2001 | CA2391925A1 Antibodies |
| 05/25/2001 | CA2391913A1 Novel thiazolidinedione derivatives as antidiabetic agents |
| 05/25/2001 | CA2391881A1 Transfer compounds, production and use thereof |